参考文献/References:
[1] Arnett DK,Blumenthal RS,Albert MA,et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,140(11):e596-e646.
[2] Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,139(25):e1082-e1143.
[3] Bras AL. Lipoprotein(a) is an independent predictor of CVD[J]. Nat Rev Cardiol,2018,15(12):727.
[4] Kamstrup PR,Tybjaerg-Hansen A,Steffensen R,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J]. JAMA,2015,301(22):2331-2339.
[5] O’Donoghue ML,Fazio S,Giugliano RP,et al. Lipoprotein(a),PCSK9 Inhibition,and Cardiovascular Risk[J]. Circulation,2019,139(12):1483-1492.
[6] Willeit P,Ridker PM,Nestel PJ,et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events:individual patient-data meta-analysis of statin outcome trials[J]. Lancet,2018,392(10155):1311-1320.
[7] Albers JJ,Slee A,O’Brien KD,et al. Relationship of apolipoproteins A-1 and B,and lipoprotein(a) to cardiovascular outcomes:the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)[J]. J Am Coll Cardiol,2013,62(17):1575-1579.
[8] Schmidt K,Noureen A,Kronenberg F,et al. Structure,function,and genetics of lipoprotein (a)[J]. J Lipid Res,2016,57(8):1339-1359.
[9] Cui FM,Fang F,He YM,et al. Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction[J]. Clin Chim Acta,2018,484:232-236.
[10] Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome:mechanisms and consequences[J]. Kidney Int,2016,90(1):41-52.
[11] Choe YG,Jin W,Cho YK,et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects[J]. J Gastroenterol Hepatol,2013,28(4):678-683.
[12] Iannuzzo G,Tripaldella M,Mallardo V,et al. Lipoprotein(a) where do we stand? From the physiopathology to innovative terapy[J]. Biomedicines,2021,9(7):838.
[13] Burges S,Ference BA,Staley JR,et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies:a Mendelian randomization analysis[J]. JAMA Cardiol,2018,3(7):619-627.
[14] Pan Y,Li H,Wang Y,et al. Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and Alzheimer disease: a Mendelian randomization study[J]. Stroke,2019,50(12):3532-3539.
[15] Kamstrup PR,Nordestgaard BG. Elevated lipoprotein(a) levels,LPA risk genotypes,and increased risk of heart failure in the general population[J]. JACC Heart Fail,2016,4(1):78-87.
[16] Larsson SC,Gill D,Mason AM,et al. Lipoprotein(a) in Alzheimer,atherosclerotic,cerebrovascular,thrombotic,and valvular disease:Mendelian randomization investigation[J]. Circulation,2020,141(22):1826-1828.
[17] Madsen CM,Kamstrup PR,Langsted A,et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention:a population-based study[J]. Arterioscler Thromb Vasc Biol,2020,40(1):255-266.
[18] Tsimikas S,Gordts P,Nora C,et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J,2020,41(24):2275-2284.
[19] Lippi G,Favaloro EJ,Sanchis-Gomar F. Antisense lipoprotein[a] therapy:State-of-the-art and future perspectives[J]. Eur J Intern Med,2020,76:8-13.
[20] Gaudet D,Watts GF,Robinson JG,et al. Effect of alirocumab on lipoprotein(a) over ＞/=1.5 years (from the Phase 3 ODYSSEY Program)[J]. Am J Cardiol,2017,119(1):40-46.
[21] Stulnig TM,Morozzi C,Reindl-Schwaighofer R,et al. Looking at Lp(a) and related cardiovascular risk:from scientific evidence and clinical practice[J]. Curr Atheroscler Rep,2019,21(10):37.
[22] Hovland A,Marcovina S,Hardersen R,et al. Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles[J]. Transfus Apher Sci,2012,46(1):73-76.
[23] Shlipak MG,Simon JA,Vittinghoff E,et al. Estrogen and progestin,lipoprotein(a),and the risk of recurrent coronary heart disease events after menopause[J]. JAMA,2000,283(14):1845-1852.
[24] Katzmann JL,Packard CJ,Chapman MJ,et al. Targeting RNA with antisense oligonucleotides and small interfering RNA:JACC State-of-the-Art Review[J]. J Am Coll Cardiol,2020,76(5):563-579.
[25] Shen X,Corey DR. Chemistry,mechanism and clinical status of antisense oligonucleotides and duplex RNAs[J]. Nucleic Acids Res,2018,46(4):1584-1600.
[26] Khvorova A. Oligonucleotide therapeutics-a new class of cholesterol-lowering drugs[J]. N Engl J Med
,2017,376(1):4-7,
[27] Viney NJ,Capelleveen JC,Geary RS,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a):two randomised,double-blind,placebo-controlled,dose-ranging trials[J]. Lancet,2016,388(10057):2239-2253.
[28] Koren MJ,Moriarty PM,Baum SJ,et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)[J]. Nat Med,2022,28(1):96-103.
[29] Nissen SE,Wolski K,Balog C,et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels[J]. JAMA,2022 327(17):1679-1687.
[30] Tsimikas S,Viney NJ,Hughes SG,et al. Antisense therapy targeting apolipoprotein(a):a randomised,double-blind,placebo-controlled phase 1 study[J]. Lancet,2015,386(10002):1472-1483.
[31] Springer AD,Dowdy SF. GalNAc-siRNA conjugates:leading the way for delivery of RNAi therapeutics[J]. Nucleic Acid Ther,2018,28(3):109-118.
[32] Alexander VJ,Xia S,Hurh E,et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA,triglycerides and atherogenic lipoprotein levels[J]. Eur Heart J,2019,40(33):2785-2796.
[33] Tsimikas S,Karwatowska-Prokopczuk E,Gouni-Berthold I,et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med,2020,382(3):244-255.
[34] M?kinen PI,Yl?-Herttuala S. Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis[J]. Curr Opin Lipidol,2013,24(2):116-122.
[35] Zimmermann TS,Lee AC,Akinc A,et al. RNAi-mediated gene silencing in non-human primates[J]. Nature,2006,441(7089):111-114.
[36] Tadin-Strapps M,Peterson LB,Cumiskey AM,et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids[J]. J Lipid Res,2011,52(6):1084-1097.
[37] Blom DJ,Raal FJ,Santos RD,et al. Lomitapide and mipomersen-inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis[J]. Curr Atheroscler Rep,2019,21(12):48.
[38] Santos RD,Raal FJ,Catapano AL,et al. Mipomersen,an antisense oligonucleotide to apolipoprotein B-100,reduces lipoprotein(a) in various populations with hypercholesterolemia:results of 4 phaseⅢtrials[J]. Arterioscler Thromb Vasc Biol,2015,35(3):689-699.
[39] Stein EA,Dufour R,Gagne C,et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia:results of a randomized,double-blind,placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease[J]. Circulation,2012,126(19):2283-2292.
[40] Raal FJ,Santos RD,Blom DJ,et al. Mipomersen,an apolipoprotein B synthesis inhibitor,for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia:a randomised,double-blind,placebo-controlled trial[J]. Lancet,2010,375(9719):998-1006.
[41] Mcgowan MP,Tardif JC,Ceska R,et al. Randomized,placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy[J]. PLoS One,2012,7(11):e49006.
[42] Li N,Li Q,Tian XQ,et al. Mipomersen is a promising therapy in the management of hypercholesterolemia:a meta-analysis of randomized controlled trials[J]. Am J Cardiovasc Drugs,2014,14(5):367-376.
[43] Reeskamp LF,Kastelein JP,Moriarty PM,et al. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia[J]. Atherosclerosis,2019,280:109-117.
[44] Cartier JL,Goldberg AC. Familial hypercholesterolemia:advances in recognition and therapy[J]. Prog Cardiovasc Dis,2016,59(2):125-134.
[45] Emdin CA,Khera AV,Natarajan P,et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels[J]. J Am Coll Cardiol,2016,68(25):2761-2772.
[46] Lamina C,Kronenberg F,Lp GC. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes:a Mendelian randomization analysis[J]. JAMA Cardiol,2019,4(6):575-579.
[47] Hovingh GK,Kastelein JJP,Van-Deventer SJH,et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP):a randomised,double-blind,placebo-controlled phase 2 trial[J]. The Lancet,2015,386(9992):452-460.
[48] Leebmann J,Roeseler E,Julius U,et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy,lipoprotein(a)-hyperlipoproteinemia,and progressive cardiovascular disease:prospective observational multicenter study[J]. Circulation,2013,128(24):2567-2576.
[49] Duell PB,Santos RD,Kirwan BA,et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia[J]. J Clin Lipidol,2016,10(4):1011-1021.